52335-75-8

Basic information

• Product Name: 1-(4-METHOXY-1H-INDOL-3-YL)-N,N-DIMETHYLMETHANAMINE
• Synonyms: 1-(4-METHOXY-1H-INDOL-3-YL)-N,N-DIMETHYLMETHANAMINE
• CAS NO: 52335-75-8
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• Mol File: 52335-75-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 334.7°C at 760 mmHg
• Flash Point: 156.2°C
• Appearance: /
• Density: 1.119g/cm³
• Vapor Pressure: 0.000126mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: 1-(4-METHOXY-1H-INDOL-3-YL)-N,N-DIMETHYLMETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-METHOXY-1H-INDOL-3-YL)-N,N-DIMETHYLMETHANAMINE(52335-75-8)
• EPA Substance Registry System: 1-(4-METHOXY-1H-INDOL-3-YL)-N,N-DIMETHYLMETHANAMINE(52335-75-8)

Safety Data

• Hazardous Substances Data: 52335-75-8(Hazardous Substances Data)

Usage

General Description

1-(4-Methoxy-1H-indol-3-yl)-N,N-dimethylmethanamine is a chemical compound with the molecular formula C13H18N2O. It is a derivative of indole and is classified as a dimethyltryptamine analog. 1-(4-METHOXY-1H-INDOL-3-YL)-N,N-DIMETHYLMETHANAMINE is a psychoactive substance and has been described as a hallucinogen and entheogen. It is often referred to as "4-MeO-DMT" and is known to interact with serotonin receptors in the brain, leading to various psychoactive effects. The compound is not approved for medical use and is considered illegal in many countries due to its hallucinogenic properties.

InChI:InChI=1/C12H16N2O/c1-14(2)8-9-7-13-10-5-4-6-11(15-3)12(9)10/h4-7,13H,8H2,1-3H3

Upstream product

• 50-00-0 formaldehyd 
• 4837-90-5 4-methoxy-1H-indole 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 
• 33797-51-2 eschenmoser's salt 
• 7732-18-5 water 
• 64-19-7 acetic acid 
• 90734-97-7 4-methoxyindole-3-carboxaldehyde 

Downstream Products

• 4837-74-5 arvelexin 
• 1240407-20-8 4-(4-iodophenyl)-1-((4-methoxy-1H-indol-3-yl)methyl)-piperidin-4-ol 
• 199540-73-3 4-Methoxy-tryptophan 
• 507268-57-7 diethyl 2-(4-methoxy-1H-indol-3-ylmethyl)-2-phenylacetylaminomalonate 
• 406938-58-7 N-Boc-D-AlaThz-Trp-(4-OMe)Trp-Gly-D-Abu-(Ph)Sec-Sar-OEt 
• 406938-59-8 Cyclo[D-AlaThz-L-Trp-L-(4-OMe)Trp-Gly-D-Aby-L-(Ph)Sec-Sar] 
• 406938-49-6 N^α-Cbz-Trp-(4-OMe)Trp-Gly-OMe 
• 406938-55-4 N^α-Cbz-(4-OMe)Trp-Gly-OMe 
• 406938-51-0 (S)-2-benzyloxycarbonylamino-3-(4-methoxy-1H-indol-3-yl)propionic acid 
• 406938-52-1 3-(4-methoxy-1H-indol-3-yl)-2-phenylacetylaminopropionic acid 
• 406938-53-2 4-methoxy-L-tryptophan 

Relevant articles and documents

SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS

Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.

Rhodium-Catalyzed Enantioselective Cyclization of 3-Allenyl-indoles: Access to Functionalized Tetrahydrocarbazoles

A highly selective rhodium-catalyzed cyclization of tethered 3-allenylindoles is reported. In a smooth reaction, 1-vinyltetrahydrocarbazoles are obtained in excellent yields and enantioselectivities. Aside from a great functional group tolerance, this method requires neither the Schlenk technique nor the use of anhydrous solvents. Preliminary mechanistic investigations proved that the reaction proceeds via an intermediary formed spiroindolenine which rapidly undergoes an acid-catalyzed stereospecific migration.

New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations

Members of the kinesin superfamily are involved in key functions during intracellular transport and cell division. Their involvement in cell division makes certain kinesins potential targets for drug development in cancer chemotherapy. The two most advanc